References
- Phillips A, Demarest K, Hahn D W., et al. Progestation al and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990; 4(4)399–410
- Corson S L. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. US clinical trials. Acta Obstet Gynecol Scand Suppl 1990; 69: 25–31
- Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1990; 69: 33–39
- Chapdelaine A, Desmarais J L., Derman R J. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil. 1989; 34: 347–52
- Taylor R. LIFETAB User's Manual. Design and Analysis Division, International Fertility Research Program, Research Triangle Park, NC 1977
- Potter R G., Jr. Use-effectiveness of intrauterine contraception as a problem in competing risks. Family Planning in Taiwan. Appendix X-2, R Freedman, J Takeshita. Princeton University Press, Princeton, NJ 1969
- Commission on Professional and Hospital Activities. International Classification of Diseases. 9th revision. Clinical Modification Volumes 1 and 2, Ann Arbor, MI 1978
- US Food and Drug Administration. National Adverse Drug Reaction Directory, COSTART Rockville, MD 1970
- Trussell J, Hatcher R A., Cates W, Jr., et al. A guide to interpreting contraceptive efficacy studies. Obstet Gynecol 1990; 76: 558–67